Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis

Clin Kidney J. 2012 Jun;5(3):240-3. doi: 10.1093/ckj/sfs031. Epub 2012 Mar 29.

Abstract

In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.

Keywords: FGF23; mineral metabolism; osteomalacia; phosphate.

Publication types

  • Case Reports